Vorinostat-induced acetylation-enhanced tyrosine kinase phosphorylation of EGFR may overcome or delay the development of acquired resistance to gefitinib caused by the low abundance of EGFR-mutant cancer cells. This evidence concerns the gene EGFR and cancer.